NEW APPROACHES TO PRECLINICAL DIAGNOSIS OF PROSTATE CANCER
https://doi.org/10.24884/1561-6274-2017-21-5-86-99
Abstract
THE AIM: to evaluate the clinical significance of the use of prostate-specific antigen (PSA) and its fractions and indexes for early detection of prostate cancer (PCA) in men with total PSA (tPSA) 2-10 ng/ml with a negative digital rectal examination (DRE).
MATERIALS AND METHODS. It were examined 904 men aged 45-80 years with tPSA 2-10 ng/ml (Hybritech calibration) and a negative result DRE. Morphologic study of 628 people were identified benign prostatic hyperplasia (BPH) and 276 – PCA. All patients underwent ultrasound examination of the prostate, with determined total PSA (tPSA) concentration, its fractions and indexes.
RESULTS. In PCA, the relative concentrations in the serum free PSA was 19% lower and the absolute content [-2]proPSA at 42% higher, and the prostate health idex (PHI) – at 49% higher. At low values of tPSA for prostate cancer would not be diagnosed in 9%, and at normal values of – 28% of patients. The sensitivity of the method at tPSA of 4.0 to 10.0 ng/ml is 0,630 and specificity of 0,519. tPSA, %fPSA were negative, but [-2]proPSA, %[-2] proPSA and PHI is positively correlated with the Gleason sum. All indicators in stage 2 for PCA are significantly different from the values characteristic of stage 1 of the disease. Though, for commonly used metrics – tPSA, fPSA and %fPSA – differences did not exceed 22-27%. However, [-2] proPSA, %[-2]proPSA and PHY at stage 2a increased by 20-53%, and at stage 2b – by 55-77%.
CONCLUSION. The most informative indicators for early diagnosis of PCA was PHY, [-2]propsa. Determinatioms of PHY in the dynamics within the screening can substantially improve early diagnosis of PCA.
About the Authors
E. S. Nevirovich
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
MD, PhD, Department of urology with the course of urology and clinic,
197022 St-Petersburg, L. Tolstoy st., 17, build. 54
A. G. Boriskin
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Associate Professor, MD, PhD, Department of urology with the course of urology and clinic,
197022 St-Petersburg, L. Tolstoy st., 17, build. 54
References
1. Siegel R, Naishadman D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1): 11-30
2. Чиссов ВИ, Русаков ИГ. Заболеваемость раком предстательной железы в Российской Федерации. Экспериментальная и клиническая урология 2011; 2–3: 6–7 [Chissov VI, Rusakov IG. Zabolevaemost’ rakom predstatel’noj zhelezy v Rossiyskoy Federacii. Jeksperimental’naja i klinicheskaja urologiya 2011; 2–3: 6–7]
3. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384 (9959): 2027-2035
4. Невирович ЕС, Яковенко АА, Румянцев АШ и др. Новые возможности в лабораторной диагностике рака предстательной железы. Дальневосточный медицинский журнал 2017; 1: 38-40 [Nevirovich ES, Jakovenko AA, Rumyantsev ASh i dr. Novye vozmozhnosti v laboratornoj diagnostike raka predstatel’noj zhelezy. Dal’nevostochnyj medicinskiy zhurnal 2017; 1: 38-40]
5. Невирович ЕС, Яковенко АА, Румянцев АШ и др. Клиническое применение индекса здоровья предстательной железы для раннего выявления рака предстательной железы у мужчин с уровнем общего ПСА 2-10 нг/мл. Врач 2015; 6: 63-65 [Nevirovich ES, Jakovenko AA, Rumyantsev ASh et al. Klinicheskoe primenenie indeksa zdorov’ya predstatel’noj zhelezy dlya rannego viyavleniya raka predstatel’noy zhelezy u muzhchin s urovnem obshhego PSA 2-10 ng/ml. Vrach 2015; 6: 63-65]
6. Chan TY, Mikolajczyk SD, Lecksell K et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 2003; 62 (1): 177-181
7. Mikolajczyk SD, Marker KM, Millar LS et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001; 61 (18): 6958-6963
8. Jansen FH, Roobol MJ, Jenster G et al. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol 2009; 55 (3): 563-574
9. Le BV, Griffin CR, Loeb S et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010; 183 (4): 1355-1359
10. Давыдов МИ, Аксель ЕМ ред. Статистика злокачественных новообразований в России и странах СНГ в 2012г. ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, М., 2013: 232 с [Davydov MI, Aksel' EM, red. Statistika zlokachestvennyh novoobrazovanij v Rossii i stranah SNG v 2012g. M.: FGBU «MNIOI im. P.A. Gercena» Minzdrava Rossii, 2013: 232s]
11. Skolarus TA, Wolf AM, Nicole L. Erb NL et al. American Cancer Society Prostate Cancer Survivorship Care Guidelines. CA Cancer J Clin 2014; 64 (4): 225-249
12. Невирович ЕС, Аль-Шукри АС, Борискин АГ и др. Роль определения уровня устойчивых изоформ простатспецифического антигена и расчета индекса здоровья простаты в ранней диагностике рака предстательной железы. Урологические ведомости 2015; 5 (1): 21-22 [Nevirovich ES, Al'-Shukri AS, Boriskin AG i dr. Rol' opredeleniya urovnya ustoychivyh izoform prostatspecificheskogo antigena i rascheta indeksa zdorov'ya prostaty v ranney diagnostike raka predstatel'noy zhelezy. Urologicheskie vedomosti 2015; 5 (1): 21-22]
13. Будылев СА, Невирович ЕС, Яковенко АА и др. Опыт применения безгазовой лапароскопии в урологии. Современные проблемы науки и образования 2015; 5: 27 [Budylev SA, Nevirovich ES, Jakovenko AA et al. Opyt primeneniya bezgazovoy laparoskopii v urologii. Sovremennye problemy nauki i obrazovaniya 2015; 5: 27]
14. Abrate A, Lughezzani G, Gadda GM et al. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature. Korean J Urol 2014; 55 (7): 436-445
Review
For citations:
Nevirovich E.S., Boriskin A.G. NEW APPROACHES TO PRECLINICAL DIAGNOSIS OF PROSTATE CANCER. Nephrology (Saint-Petersburg). 2017;21(5):65-70. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-5-86-99
Views:
1104
Email this article 